Summary
OBJECTIVEThis is the first study to determine whether there is a relationship between penile bulb radiation dose and urinary incontinence.
METHODS
This study comprises 131 patients with localized, locally advanced, and pelvic oligometastatic prostate
cancer treated at our institution. All patients were treated with IMRT between February 2016 and August
2020. Urinary incontinence after the treatment was assessed retrospectively using a standardized
follow-up program based on data available at our center. The urinary incontinence was scored using the
CTCAE version 5.0 scoring system. In univariate analysis, the Mann-Whitney test was used to detect any
association between penile bulb V50 doses and membranous urethral length on urinary incontinence.
RESULTS
Urinary incontinence after the treatment was reported in 17 of 131 patients. The average penile bulb V50
values of patients with incontinence were 28.66 gy and 26.8 in patients who did not have urinary incontinence.
The mean membranous urethral length was 3.01cm in patients with incontinence and 3.34cm
in patients without incontinence. Although these parameters have minimal difference in patients with
and without incontinence, they are not statistically significant (p>0.05 all).
CONCLUSION
Radiation-induced urinary incontinence was not associated with the radiation dose of the penile bulb
and membranous urethral length. However, further studies are essential.
Introduction
The use of radiation therapy to treat prostate cancer inevitably involves exposure of normal tissues. As a result, patients may experience symptoms associated with damage to normal tissue after the therapy. Urinary incontinence is one of the most clinically relevant side effects in the treatment of prostate cancer patients.[1]There are many known anatomical and physiological parameters related to urinary continence. Rehder et al.[2] described the effect of the penile bulb on urinary continence for the first time. This was based on the idea that physiological contraction of the bulbospongiosus muscle increases pressure in the bulb of the penis (as blood is not compressible) and consecutively leads to additional contraction of the urethral lumen. Based on this knowledge, a well-vascularized penile bulb is important to erectile function and urinary continence. There are several clinical studies that support this view.[3,4] These studies are about the relationship between continence surgery and male sexual function. No study has yet evaluated the penile bulb radiation dose effect on continence.
As we know, radiation treatment affects normal tissue vasculature near the target volume. We searched about the effect of this damage on the penile bulb and related urinary incontinence.
Methods
This retrospective cohort study was composed of 131 patients with localized, locally advanced, and pelvic oligometastatic prostate cancer (excluding distant metastasis). Genitourinary (GU) toxicity was assessed using a standardized follow-up program retrospectively. The GU toxicity endpoints were scored using the Common Terminology Criteria for Adverse Events version 5.0 (CTCAE 5.0) scoring system. The full bladder, different anatomical subregions within the bladder, penile bulb, and membranous urethral length (MUL) were delineated on computed tomography simulation (CT-sim).
Patients
This retrospective cohort study was composed of 131
patients with localized, locally advanced prostate cancer
and pelvic oligometastatic disease. We excluded
extrapelvic-distant metastatic prostate cancer patients
from the study. All patients were treated with radiotherapy
between February 2016 and August 2020. Of the
131 patients, 30 were those who had undergone radical
prostatectomy (salvage prostatectomy was excluded).
Urinary incontinence that occurred after the treatment
was evaluated. Radiotherapy was delivered using linear
accelerators with 6 MV photons by intensity-modulated
radiotherapy (IMRT). Patients were treated five times
per week at doses ranging from 66 to 76 Gy at the planning
target volume (PTV) using a standard 2 Gy per
fraction. Six of the patients consisted of those treated
with the hypofractionated regimen (2 Gy < per fraction).
In the current patient cohort, 36.6% of patients
had irradiated pelvic lymph nodes as part of therapy.
Setup accuracy was verified during delivery by matching
bony anatomy. Most patients with locally advanced
prostate cancer received adjuvant hormonal treatment.
Diabetes, hypertension, coronary artery disease, and
peripheral artery disease were defined as "vascular diseases".
Other diseases, such as endocrinological and
rheumatological, were described as "other than vascular
disease". These patient characteristics were retrospectively
assessed from detailed patient charts (Table 1).
Table 1 Patient and treatment characteristics
Target and Organ at Risk Delineation
The high-risk clinical target volume (HR-CTV) consisted
of the prostate with or without the SV, depending on
the estimated risk of SV invasion. Due to the risk of locoregional
metastases, pelvic lymphatics are included in
the low-risk clinical target volume (LR-CTV). The full
bladder was applied as part of the treatment planning.
Patients were instructed to urinate and drink half or one
liter of water one hour before the radiotherapy. The penile
bulb contouring was done with the ESTRO-ACROP
guidelines.[5] The bladder was created using the entire
bladder. The trigone was defined as the triangle-shaped
structure between the transition of the ureters in the
bladder wall cranially and the transition of the urethra
into the bladder wall caudally.[6] MUL was measured in
the midline sagittal plane on CT-sim. On CT-sim with
non-operated patients, MUL was considered to be the
distance from the prostatic apex to the level of the urethra
at the penile bulb (Fig. 1). With operated patients,
MUL was supposed to be the distance from the bladder
neck to the layer of the urethra at the penile bulb.[7]
Endpoints
The grade of urinary incontinence according to CTCAE
v5.0 was evaluated retrospectively using available
patient data between 2016 and 2020. Urinary incontinence
grade 1 was defined as occasional leaking (e.g.,
with coughing, sneezing, etc.) when pads were not
indicated, while grade 2 was defined as spontaneous
leaking when pads were indicated. In addition, the operation
intervention is only applied to grade 3. Urinary
incontinence was evaluated for the first six months after
treatment. Late urinary incontinence and recovery
of incontinence were not evaluated.
Statistical Analysis
In univariate statistical analysis, the Mann-Whitney
test was used to detect any association between penile
bulb V50-V60 doses and membranous urethral length
on urinary incontinence. Besides, the variables of age,
comorbidity, operation, hormone therapy, bladder, and
trigonum doses were compared to perform a univariate
analysis. p value < 0.05 was considered significant. The
statistical analysis was performed using IBM SPSS 22.0.
Results
Urinary incontinence after the treatment was reported in 17 of 131 patients. Sixteen of them were grade 1-2 incontinence. Grade 3 incontinence was reported in one patient. This patient belonged to the group of patients who had undergone a radical prostatectomy. No grade 4-5 incontinence was reported. The penile bulb V50 values and membranous urethral length were evaluated in the univariate analysis. In the study, the average penile bulb V50 values of patients with incontinence were 28.66. In addition, the penile bulb V50 doses were 26.8 in patients who did not have urinary incontinence. The mean membranous urethral length was 3.01 cm in patients with incontinence and 3.34 cm in patients without incontinence.Although there is minimal change in these parameters in patients with incontinence, they are not statistically significant (p>0.05 all). The variables of age, comorbidity, operation, hormone therapy, bladder, and trigonum doses were compared to perform a univariate analysis. The only association with incontinence was found with radical prostatectomy (p=0.021) (Table 2).
Table 2 Urinary incontinence related parameters
Discussion
Many factors cause urinary incontinence in patients undergoing prostate cancer treatment. One of these is the postoperative membranous urethral length (MUL). Negative impacts on urinary incontinence have been shown in studies.[8-11] These studies have found that MUL is associated with recovery of incontinence. We evaluated this parameter in our study. However, our study did not reach similar results because urinary incontinence recovery was not assessed.There is an idea that physiological contraction of the bulbospongiosus muscle increases pressure in the bulb of the penis (as blood is not compressible) and consecutively leads to additional contraction of the urethral lumen. A well-vascularized penile bulb is an essential factor in this mechanism. Radiotherapy reduces the blood supply to these anatomic regions, and our study was based on this idea.
The proximal male urethral bulb is an integrated part of the urinary continence mechanism, especially during increased physical activity. Several clinical studies support this view.[3-5] However, these studies have demonstrated that urinary incontinence correlated with sexual function on surgical techniques. No study has yet evaluated the penile bulb radiation dose (sexual function) effect on continence. This study is the first on this aspect.
We have found no relation between urinary incontinence and penile bulb radiation doses. There could be several explanations for this result. The most important one is that we have a short period of follow-up time data retrospectively (six months), so there was no evaluation of late urinary incontinence and recovery. Just like the other factors, it should be kept in mind that penile bulb radiation dose may be associated with incontinence recovery. The second is that we do not use any side effect scoring questionnaires. The clinician"s patient records were used for grading urinary incontinence (CTCAE v5.0) retrospectively. This means there may be missing records.
Conclusion
Our study showed that there is no relationship between penile bulb radiation dose and urinary incontinence. Besides that, considering the limitations of our study and the studies supporting the correlation between sexual function and urinary incontinence, further studies are essential. We suggest that future studies should be prospective; continence recovery and late urinary incontinence should be examined.Ethics Committee Approval: The study was approved by the Gazi University Ethics Committee (no: E-77082166- 604.01-1006859, date: 31/07/2024).
Authorship contributions: Concept - M.A.; Design - M.A., Ş.D.; Supervision - M.A., Ş.D.; Materials - Ş.D.; Data collection and/or processing - Ş.D., M.E.Ş.; Data analysis and/or interpretation - Ş.D.; Literature search - Ş.D.; Writing - Ş.D.; Critical review - M.A., Ş.D.
Conflict of Interest: All authors declared no conflict of interest. Use of AI for Writing Assistance: Not declared.
Financial Support: None declared.
Peer-review: Externally peer-reviewed.
References
1) Schwartz K, Bunner S, Bearer R, Severson RK. Complications
from treatment for prostate carcinoma among
men in the Detroit area. Cancer 2002;95(1):82-9.
2) Rehder P, Staudacher NM, Schachtner J, Berger ME,
Schillfahrt F, Hauser V, et al. Hypothesis that urethral
bulb (corpus spongiosum) plays an active role in male
urinary continence. Adv Urol 2016;2016:6054730.
3) Chung E, Wang J. The AdVance sling and male sexual
function: A prospective analysis on the impact of pelvic
mesh on erectile and orgasmic domains in sexually
active men with postprostatectomy stress urinary incontinence.
Sex Med 2022;10(4):100529.
4) Queissert F, Rourke K, Schönburg S, Giammò A, Gonsior
A, González-Enguita C, et al. ATOMS (Adjustable
Transobturator Male System) is an effective and safe second-line treatment option for recurrent urinary incontinence
after implantation of an AdVance/AdVance
XP fixed male sling? A multicenter cohort analysis. J
Clin Med 2021;11(1):81.
5) Salembier C, Villeirs G, De Bari B, Hoskin P, Pieters
BR, Van Vulpen M, et al. ESTRO ACROP consensus
guideline on CT-and MRI-based target volume delineation
for primary radiation therapy of localized
prostate cancer. Radiother Oncol 2018;127(1):49-61.
6) Ghadjar P, Zelefsky MJ, Spratt DE, af Rosenschöld PM,
Oh JH, Hunt M, et al. Impact of dose to the bladder
trigone on long-term urinary function after high-
-dose intensity modulated radiation therapy for localized
prostate cancer. Int J Radiat Oncol Biol Phys
2014;88(2):339-44.
7) Lin D, O"Callaghan M, David R, Fuller A, Wells R,
Sutherland P, et al. Does urethral length affect continence
outcomes following robot assisted laparoscopic
radical prostatectomy (RALP)? BMC Urol 2020;20:1-7.
8) Matsushita K, Kent MT, Vickers AJ, von Bodman C,
Bernstein M, Touijer KA, et al. Preoperative predictive
model of recovery of urinary continence after radical
prostatectomy. BJU Int 2015;116(4):577-83.
9) Nguyen L, Jhaveri J, Tewari A. Surgical technique
to overcome anatomical shortcoming: Balancing
post-prostatectomy continence outcomes of urethral
sphincter lengths on preoperative magnetic resonance
imaging. J Urol 2008;179(5):1907-11.